(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.34%) $82.73
(6.55%) $2.05
(0.01%) $2 347.50
(-0.35%) $27.44
(4.08%) $959.75
(-0.21%) $0.933
(-0.33%) $10.99
(-0.53%) $0.796
(1.55%) $93.30
Live Chart Being Loaded With Signals
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA...
Stats | |
---|---|
Dagens volum | 245 298 |
Gjennomsnittsvolum | 564 056 |
Markedsverdi | 0.00 |
EPS | $0 ( 2023-03-13 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0.0560 (0.37%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-01-19 | Bate Kenneth | Sell | 375 | Common Stock |
2023-01-19 | Bate Kenneth | Sell | 22 500 | Stock Option (Right to Buy) |
2023-01-19 | Evnin Anthony B | Sell | 22 500 | Stock Option (Right to Buy) |
2023-01-19 | Ledell Jebediah | Sell | 27 702 | Stock Option (Right to Buy) |
2023-01-19 | Ferraresso Michael | Sell | 220 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
46.33 |
Last 96 transactions |
Buy: 43 011 518 | Sell: 9 966 796 |
Volum Korrelasjon
Aveo Pharmaceuticals Inc Korrelasjon
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Aveo Pharmaceuticals Inc Korrelasjon - Valuta/Råvare
Aveo Pharmaceuticals Inc Økonomi
Annual | 2021 |
Omsetning: | $38.87M |
Bruttogevinst: | $34.14M (87.81 %) |
EPS: | $-2.49 |
FY | 2021 |
Omsetning: | $38.87M |
Bruttogevinst: | $34.14M (87.81 %) |
EPS: | $-2.49 |
FY | 2020 |
Omsetning: | $6.02M |
Bruttogevinst: | $4.77M (79.32 %) |
EPS: | $-1.660 |
FY | 2019 |
Omsetning: | $28.80M |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $0.610 |
Financial Reports:
No articles found.
Aveo Pharmaceuticals Inc
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.